Overview

Rituximab at Low dosE for neuromyelitiS optiCa spectrUm disordEr (RESCUE)

Status:
Completed
Trial end date:
2020-06-01
Target enrollment:
Participant gender:
Summary
In this research, a prospective, multicenter(Tangdu Hospital of Fourth Military Medical University, Xi'an Gaoxin Hospital of Xi'an Medical College, Xianyang Central Hospital, Baoji Central Hospital, Xi'an Central Hospital, The First Hospital of Xi'an, The Fourth Hospital of Xi'an) open-label, follow-up clinical trial will carry out to evaluate the efficacy and safety of low-dose rituximab in treating NMOSD in Northwest China.
Phase:
Phase 4
Details
Lead Sponsor:
Tang-Du Hospital
Treatments:
Rituximab